BMEA Biomea Fusion, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1840439 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY76.7%
TTM EPS YoY95.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-192.3%
ROA-53.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets73.0%
Debt / equity0.00x
Current ratio2.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.98x
Accruals ratio52.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $61.98M | $118.08M | $102.55M | $62.71M | $28.00M |
| SG&A expense | $19.33M | $25.98M | $23.59M | $20.92M | $13.67M |
| Operating income | -$83.51M | -$144.07M | -$126.14M | -$83.63M | -$41.67M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$61.80M | -$138.43M | -$117.25M | -$81.83M | -$41.57M |
| EBITDA | -$82.10M | -$142.32M | -$124.62M | -$82.94M | -$41.42M |
| EPS (basic) | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 |
| EPS (diluted) | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 |
| Weighted avg. shares (diluted) | 52.23M | 36.11M | 34.11M | 29.27M | 23.86M |
| Banking | |||||
| Net interest income | $1.86M | $5.64M | $8.88M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $55.81M | $58.65M | $176.87M | $112.25M | $146.09M |
| Short-term investments | — | — | — | $1.15M | $27.78M |
| Current assets | $58.05M | $68.33M | $179.18M | $117.82M | $176.56M |
| PP&E, net | $153,000 | $3.77M | $5.16M | $5.84M | $2.96M |
| Total assets | $58.57M | $79.94M | $199.93M | $129.31M | $185.71M |
| Current liabilities | $11.10M | $21.67M | $22.86M | $19.10M | $4.64M |
| Total liabilities | $29.02M | $28.36M | $30.69M | $20.77M | $6.92M |
| Shareholders' equity | $29.55M | $51.57M | $169.24M | $108.54M | $178.78M |
| Shares outstanding | 72.30M | 36.31M | 35.87M | 29.56M | 29.12M |
| Cash flow statement | |||||
| Operating cash flow | -$70.37M | -$119.89M | -$96.59M | -$62.42M | -$35.44M |
| Capital expenditure | — | $362,000 | $3.37M | $1.03M | $3.17M |
| Free cash flow | — | -$120.26M | -$99.96M | -$63.45M | -$38.61M |
| Investing cash flow | — | -$362,000 | -$2.22M | $27.34M | -$33.35M |
| Financing cash flow | $67.90M | $1.67M | $163.80M | $1.24M | $153.19M |
| Depreciation & amortization | $1.41M | $1.75M | $1.51M | $691,000 | $249,000 |
| Stock-based compensation | $9.52M | $19.09M | $14.13M | $10.34M | $6.23M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.